Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis

Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable benefit–risk profile and attributes that encourage a high level of treatment adherence. Daclizumab is a humanized monoclonal antibody directed against CD25, the α subunit of the high-affinity interleukin 2 (IL-2) receptor, that reversibly modulates IL-2 signaling. Daclizumab treatment leads to antagonism of proinflammatory, activated T lymphocyte function and expansion of immunoregulatory CD56bright natural killer cells, and has the potential to, at least in part, rectify the imbalance between immune tolerance and autoimmunity in relapsing MS. The clinical pharmacology, efficacy, and safety of subcutaneous daclizumab have been evaluated extensively in a large clinical study program. In pivotal studies, daclizumab demonstrated superior efficacy in reducing clinical and radiologic measures of MS disease activity compared with placebo or intramuscular interferon beta-1a, a standard-of-care therapy for relapsing MS. The risk of hepatic disorders, cutaneous events, and infections was modestly increased. The monthly subcutaneous self-injection dosing regimen of daclizumab may be advantageous in maintaining patient adherence to treatment, which is important for optimal outcomes with MS disease-modifying therapy. Daclizumab has been approved in the US and in the European Union and represents an effective new treatment option for patients with relapsing forms of MS, and is currently under review by other regulatory agencies.

Keywords: daclizumab, disease-modifying therapy, humanized monoclonal antibody, relapsing multiple sclerosis, therapeutic use

Introduction

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, and degenerative disorder of the brain, optic nerves, and spinal cord. MS affects an estimated 2.3 million people worldwide, with a global median prevalence of 33 cases per 100,000 people. The prevalence is highest in North America and Europe. MS is most commonly diagnosed between the ages of 20 and 40 years, affects approximately two to three times as many women as men, and is the most frequent chronic disabling neurologic disease in young adults in the industrialized world.

In the relapsing form of MS (RMS), autoreactive lymphoid cells directed against central nervous system (CNS) antigens are activated in the periphery and subsequently migrate into the CNS, producing multifocal inflammatory lesions that result in demyelination and axonal transection, thereby giving rise to the characteristic acute or subacute neurologic symptoms of a relapse. Relapses are transient and followed...
by complete or incomplete clinical recovery, which may result from resolution of inflammatory activity and a variable degree of remyelination. The use of corticosteroids during relapses may shorten the duration and/or the intensity of inflammation. If left untreated, recurring relapses and residual damage can result in worsening sustained neurological disability as a consequence of irreversible axonal damage and neurodegeneration, as well as significant reduction in health-related quality of life and shortened life expectancy.

The interferon beta products (eg, Betaseron/Betaferon [Bayer HealthCare Pharmaceuticals Inc., Montville, NJ, USA/Bayer Pharma AG, Berlin, Germany], Avonex [Biogen, Cambridge, MA, USA], Rebif [EMD Serono, Rockland, MA, USA], Extavia [Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA]) and glatiramer acetate (Copaxone [Teva Pharmaceuticals, North Wales, PA, USA], which were approved by the US Food and Drug Administration (US FDA) or the European Medicines Agency (EMA) between 1993 and 2002, reduced the frequency of relapses in clinical studies by -30% compared with placebo over a 2- to 3-year period of observation. Interferon beta-1a (Avonex and Rebif) also was shown to reduce the risk of confirmed disability worsening. These products, which appear to have broad-spectrum immune-modulating properties, were the first proven disease-modifying therapies (DMTs) for the chronic treatment of RMS.

Mitoxantrone (Novantrone; EMD Serono), an antineoplastic agent that damages and prevents the repair of DNA and interferes with RNA function, was approved for the treatment of aggressive relapsing–remitting, secondary-progressive, and progressive-relapsing MS in the early 2000s, but it has largely fallen out of use because of limitations in dosage and duration of use due to its potential for serious cardiac toxicity and a heightened risk of acute myeloid leukemia.

The use of more targeted therapies that regulate immune pathways mediating CNS damage in RMS was first established with the approval of natalizumab (Tysabri; Biogen), a humanized monoclonal antibody that selectively inhibits inflammatory cell migration into the CNS. In clinical studies, natalizumab resulted in a robust therapeutic response, significantly reducing relapse risk, magnetic resonance imaging (MRI) measures of disease activity, and risk of confirmed disability worsening. Natalizumab also was effective on composite measures of disease activity; in a retrospective analysis of the AFFIRM study, more than 30% of natalizumab-treated patients showed no evidence of radiologic or clinical disease activity (no evidence of disease activity [NEDA]) during 2 years of treatment.

Three oral agents were subsequently approved by the FDA and EMA as MS DMTs. The first oral agent approved was fingolimod (Gilenya; Novartis AG, Basel, Switzerland), a sphingosine-1-phosphate receptor modulator. A putative mechanism of action in MS is retention of reactive memory lymphocytes in lymphoid organs. This was followed by delayed-release dimethyl fumarate (Tecfidera; Biogen), which in RMS may increase tolerance to the oxidative stress of inflammation by promoting de novo synthesis of oxidative quenching species. Teriflunomide (Aubagio; Genzyme Corporation, Cambridge, MA, USA) is reported to reduce the population of activated lymphocytes by blocking mitochondrial pyrimidine synthesis. Each of these oral agents reduces risk of relapse, disease activity as observed on MRI, and risk of confirmed disability worsening.

A more recently approved MS DMT is alemtuzumab (Lemtrada; Genzyme Corporation), an anti-CD52 monoclonal antibody that results in the sustained depletion of circulating T and B lymphocytes. Alemtuzumab results in reduced risk of relapse activity, disease activity on MRI, and risk of confirmed disability worsening. Ocrelizumab (Roche, Basel, Switzerland) is unique among the MS DMTs because it has shown significant treatment benefits in Phase III clinical studies in both RMS versus an active comparator and in primary progressive MS versus placebo. Ocrelizumab is an anti-CD20 monoclonal antibody that causes selective and sustained depletion of CD20 B lymphocytes and has been submitted for regulatory approval as an MS DMT.

While many of the recent therapeutic developments for MS were driven by a greater understanding of immune system function, such as the regulatory role of the α 4-integrin receptor subunit (blocked by natalizumab) on the ingress of activated peripheral lymphocytes and monocytes into the CNS and the sequestration of activated lymphocytes in peripheral lymphoid organs (enhanced by fingolimod), these agents also are noneselective in the sense that they exploit the inhibition of aspects of overall general immune responsiveness as a mechanism to block autoimmunity. One potential consequence of broad inhibition of immune system response is increased risk of infection, including opportunistic infection, which has been encountered with some MS DMTs.

An alternative therapeutic approach is to attempt to reestablish equilibrium between autoimmunity and self-tolerance as a means of controlling the abnormal autoreactive state driving MS. Daclizumab, a humanized monoclonal antibody that blocks the α subunit (CD25) of the interleukin 2 (IL-2) receptor (IL-2R), has the potential to restore the homeostasis...
between autoimmunity and autotolerance that is characteristic of the nondisease state.39,40 Daclizumab has been shown to reduce the expansion of proinflammatory, activated T lymphocytes, and it may simultaneously promote autotolerance through the expansion of CD56bright natural killer (NK) cells, and at least partially preserve the regulatory T cell (TREG) population and function.46 Daclizumab high-yield process (daclizumab [Zinbryta™ [Biogen, Cambridge, MA, USA and AbbVie Inc., North Chicago, IL, USA]]) was approved for noninvestigational use in the US and in the European Union as a once-monthly subcutaneous (SC) injection for the treatment of RMS in May and July 2016, respectively. As described in more detail in the following section, daclizumab reduced relapse risk, disease activity as monitored by MRI, and risk of confirmed disability worsening in pivotal controlled clinical studies.41,42

Proof of concept and the clinical development program

A previous form of daclizumab was developed as an intravenous (IV) therapy (Zenapax®; Hoffmann-La Roche Ltd, Nutley, NJ, USA) and was used as part of a prophylactic drug regimen in patients with a renal transplant to prevent acute organ rejection and for prevention of severe sight-threatening intraocular inflammation in patients with uveitis.39 Because RMS and solid-organ graft rejection are both associated with pathologically heightened effector T lymphocyte activity, it was hypothesized that daclizumab could be of clinical benefit in patients with active RMS.39,43 Subsequent small-scale open-label clinical studies showed promising results.45–46 Daclizumab was reformulated as an SC injection and tested as an adjunct to interferon beta in the Phase II, multicenter, randomized, double-blind CHOICE study, which assessed its efficacy and safety in patients with active RMS.47 CHOICE demonstrated that daclizumab as an add-on therapy with interferon beta reduced disease activity on MRI compared with interferon beta alone.47

Based on these positive results, daclizumab high-yield process was subsequently developed. Daclizumab high-yield process has an identical amino acid sequence and the same antigen-binding domain as earlier forms of daclizumab, but differs in its glycosylation profile, leading to altered binding at the Fc receptor. This new form of daclizumab has been associated with less antibody-dependent cell-mediated cytotoxicity compared with earlier forms of daclizumab.56 In the multicenter, randomized, double-blind, placebo-controlled (SELECT) and active-comparator (DECIDE) clinical studies, daclizumab monotherapy, administered SC every 4 weeks, resulted in statistically significant reductions in both clinical and MRI indicators of disease activity in patients with RMS.41,42 These studies are described in detail in a later section of this review.

The clinical pharmacology, efficacy, and safety of SC daclizumab has been evaluated extensively in Phase I pharmacokinetic studies;58 an open-label safety, immunogenicity, pharmacokinetic, and pharmacodynamic study;59,60 and randomized, double-blind, placebo- and active-controlled studies, and their extension phases (Table 1 and Figure 1).41,42,51–53

Pharmacology

Mechanism of action

The putative mechanism of action for daclizumab is unique compared with other approved DMTs for the treatment of RMS. As described earlier, daclizumab is a monoclonal antibody that binds to the α subunit (CD25) of the IL-2R expressed on activated T lymphocytes, thereby preventing interaction of IL-2 with its high-affinity receptor and inhibiting the activation of CNS antigen-experienced, proinflammatory, activated T lymphocytes,39,54–57 one of the main drivers of MS pathogenesis.4

The IL-2/IL-2R pathway also has an important role in maintaining the homeostatic balance between proinflammatory autoimmunity and anti-inflammatory autotolerance.40 The cytokine IL-2 is a lymphocyte growth factor produced primarily by activated CD4+ T lymphocytes, and to a lesser degree by CD8+ T lymphocytes, dendritic cells, and NK cells.58 Antigen presentation to T lymphocytes promotes both IL-2 production and secretion by these antigen-activated T lymphocytes and also upregulates IL-2R expression on T lymphocytes.59–61 The IL-2/IL-2R interaction drives T lymphocyte clonal expansion when an immune response is mounted, as is the case in autoimmune conditions such as MS.62 Production of IL-2 is generally short lived, and IL-2 levels are regulated by an autoinhibitory feedback loop such that IL-2 binding to IL-2R activates secondary intracellular messenger systems to repress the IL2 gene.63–65 This process serves to reduce or prevent prolonged T lymphocyte–driven inflammatory responses. IL-2 signaling through IL-2R also is necessary for the support and function of TREG cells, which are required for the maintenance of autotolerance.66–72 Thus, the IL-2/IL-2R system provides a mechanism for both upregulation of proinflammatory responses and maintenance of immune homeostasis.

Evidence suggests that MS may result, in part, from a breakdown in immune self-tolerance due to abnormalities in the IL-2/IL-2R signaling pathway, resulting in an excess of peripherally activated CNS antigen-primed T lymphocytes.40

Biologics: Targets and Therapy 2016:10

submit your manuscript | www.dovepress.com

Dovepress

Therapeutic efficacy of daclizumab for relapsing MS

121
### Table 1 Overview of completed and ongoing daclizumab clinical studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Number of participants</th>
<th>Treatment regimens</th>
<th>MRI assessments reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I studies\textsuperscript{48}</td>
<td>Completed integrated population pharmacokinetic analysis of three randomized, double-blinded, placebo-controlled studies</td>
<td>97 healthy volunteers</td>
<td>• Placebo&lt;br&gt;• Daclizumab 50, 150, or 300 mg SC single dose&lt;br&gt;• Daclizumab 200 mg SC initially and then 100 or 200 mg biweekly&lt;br&gt;• IV daclizumab 200 or 400 mg single dose</td>
<td>None</td>
</tr>
<tr>
<td>SELECT\textsuperscript{41}</td>
<td>Completed Phase II, randomized, multicenter, placebo-controlled, double-blind, 52-week study</td>
<td>621 patients with RMS</td>
<td>• Placebo SC every 4 weeks&lt;br&gt;• Daclizumab 150 mg SC every 4 weeks&lt;br&gt;• Daclizumab 300 mg SC every 4 weeks</td>
<td>All patients: baseline, weeks 24, 36, and 52&lt;br&gt;MRI-intensive subset (n=307): every 4 weeks between baseline and week 24</td>
</tr>
<tr>
<td>SELECTION\textsuperscript{52}</td>
<td>Completed Phase II, randomized, multicenter, double-blind, 52-week extension study</td>
<td>517/567 (91%) patients with RMS who completed SELECT and entered SELECTION</td>
<td>• Placebo group: re-randomized to daclizumab 150 or 300 mg SC every 4 weeks&lt;br&gt;• Daclizumab groups: re-randomized to continue same daclizumab dosage or to a 20-week placebo washout period\textsuperscript{b} followed by treatment with initial daclizumab dosage for 32 weeks</td>
<td>Baseline, weeks 20 and 52</td>
</tr>
<tr>
<td>SELECTED\textsuperscript{53,29}</td>
<td>Ongoing Phase II, multicenter, single-arm, open-label, 288-week extension study</td>
<td>410 patients with RMS who completed SELECT and entered SELECTED</td>
<td>• Daclizumab 150 mg SC every 4 weeks</td>
<td>Baseline, weeks 48 and 96</td>
</tr>
<tr>
<td>OBSERVE\textsuperscript{49}</td>
<td>Ongoing Phase III, multicenter, open-label, single-treatment-arm immunogenicity, safety/tolerability, and pharmacokinetic ≤4 year study</td>
<td>133 patients with RMS</td>
<td>• Daclizumab 150 mg SC every 4 weeks for 24 weeks, then a 20-week washout period, followed by daclizumab 150 mg SC for up to another 3 years</td>
<td>Not reported</td>
</tr>
<tr>
<td>DECIDE\textsuperscript{42,158}</td>
<td>Completed Phase III, randomized, multicenter, active-control, double-dummy, parallel-group, double-blind 96- to 144-week study</td>
<td>1,841 patients with RMS</td>
<td>• Daclizumab 150 mg SC every 4 weeks and placebo IM once weekly&lt;br&gt;• Interferon beta-1a 30 mcg IM once weekly and placebo SC every 4 weeks</td>
<td>Baseline, weeks 24, 96, and 144</td>
</tr>
<tr>
<td>EXTEND\textsuperscript{41}</td>
<td>Ongoing Phase III, open-label, extension study</td>
<td>≤1,600 patients with RMS (≤1,200 who completed DECIDE are eligible to enter at week 0. An additional ≤400 from SELECTED and OBSERVE are eligible to enter at week 144)</td>
<td>• Daclizumab 150 mg SC every 4 weeks</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

**Notes:** \textsuperscript{a}Timing of MRI assessments for each study that have been reported in the literature. \textsuperscript{b}In the placebo washout group, the total time between the last dose of daclizumab in SELECT and reinitiation in SELECTION was 24 weeks.  
**Abbreviations:** MRI, magnetic resonance imaging; SC, subcutaneous; IV, intravenous; RMS, relapsing multiple sclerosis; IM, intramuscular.

For example, polymorphisms in the CD25 gene are associated with MS susceptibility, directly implicating IL-2 signaling in MS pathogenesis.\textsuperscript{73,74} These polymorphisms also are associated with increased CD25 expression on naive CD4\textsuperscript{+} T lymphocytes.\textsuperscript{75} Levels of soluble CD25, a marker of IL-2-driven T lymphocyte proliferation,\textsuperscript{76} also are elevated in MS,\textsuperscript{77} and have been linked with MS severity.\textsuperscript{78} IL-2 signaling is mediated through two IL-2R isoforms, which differ in their affinity for IL-2 and expression across different immune cell types.\textsuperscript{79} On the surface of activated T lymphocytes and T\textsubscript{REG} cells, IL-2 signaling is mediated via the high-affinity isoform that is composed of the IL-2-capturing α subunit (CD25), which is expressed transiently following antigen activation in T lymphocytes and constitutively in T\textsubscript{REG}.
A  SELECT triology study design

SELECT  N=621  Randomized

SELECTION  N=517  Re-randomized

SELECTED  N=410  Open-label extension

Placebo

Daclizumab 150 mg

Daclizumab 300 mg

Daclizumab 150 mg

24-week placebo washout

Daclizumab 150 mg

Daclizumab 300 mg

24-week placebo washout

Daclizumab 150 mg

52 weeks

52 weeks

6 years

B  DECIDE and EXTEND study design

DECIDE  N=1,841  Randomized

EXTEND  N=1,600  Open-label extension

IM IFN beta-1a

Daclizumab 150 mg

Daclizumab 150 mg

96–144 weeks

~5 years

Notes: (A) In SELECT, patients with RMS were randomized to receive daclizumab 150 or 300 mg subcutaneously every 4 weeks or placebo for 52 weeks. Patients who completed SELECT were eligible to enroll in the SELECTION extension study. In SELECTION, patients from the placebo group in SELECT were re-randomized to receive daclizumab 150 or 300 mg subcutaneously every 4 weeks for 52 weeks; patients from the daclizumab 150 and 300 mg treatment arms in SELECT were re-randomized to continue their assigned dosage of daclizumab or to 20 weeks of placebo treatment followed by reinitiation of their previously assigned dosage of daclizumab for 32 weeks. In the placebo washout group, the period of time between the last daclizumab dose in SELECT and reinitiation of daclizumab in SELECTION was a total of 24 weeks. Patients who completed SELECTION were eligible to enroll in the ongoing open-label SELECTED study in which all patients received daclizumab 150 mg for up to 6 years.

(B) In DECIDE, patients were randomized to receive daclizumab 150 mg subcutaneously every 4 weeks or IFN beta-1a 30 mcg IM once weekly for a minimum of 96 weeks up to a maximum of 144 weeks; the study ended when the last enrolled patient completed the week 96 visit. Patients who completed DECIDE were eligible to enroll in the ongoing EXTEND safety extension study in which all patients received daclizumab 150 mg for up to 6 years of total time on treatment.

Abbreviations: IM, intramuscular; IFN, interferon; RMS, relapsing multiple sclerosis.

Figure 1 The SELECT and DECIDE studies and their extension studies.

SELECT triology study design

DECIDE and EXTEND study design

Notes: (A) In SELECT, patients with RMS were randomized to receive daclizumab 150 or 300 mg subcutaneously every 4 weeks or placebo for 52 weeks. Patients who completed SELECT were eligible to enroll in the SELECTION extension study. In SELECTION, patients from the placebo group in SELECT were re-randomized to receive daclizumab 150 or 300 mg subcutaneously every 4 weeks for 52 weeks; patients from the daclizumab 150 and 300 mg treatment arms in SELECT were re-randomized to continue their assigned dosage of daclizumab or to 20 weeks of placebo treatment followed by reinitiation of their previously assigned dosage of daclizumab for 32 weeks. In the placebo washout group, the period of time between the last daclizumab dose in SELECT and reinitiation of daclizumab in SELECTION was a total of 24 weeks. Patients who completed SELECTION were eligible to enroll in the ongoing open-label SELECTED study in which all patients received daclizumab 150 mg for up to 6 years.

(B) In DECIDE, patients were randomized to receive daclizumab 150 mg subcutaneously every 4 weeks or IFN beta-1a 30 mcg IM once weekly for a minimum of 96 weeks up to a maximum of 144 weeks; the study ended when the last enrolled patient completed the week 96 visit. Patients who completed DECIDE were eligible to enroll in the ongoing EXTEND safety extension study in which all patients received daclizumab 150 mg for up to 6 years of total time on treatment.

Abbreviations: IM, intramuscular; IFN, interferon; RMS, relapsing multiple sclerosis.
cells, and two signaling subunits, CD132 and CD122 (the γ and β chains, respectively; Figure 2). IL-2 binding to CD25 promotes the association with CD122 and CD132, resulting in the formation of the quaternary high-affinity receptor complex. CD25 functions solely to increase the affinity of IL-2R for IL-2 and has no known signaling function. Thus, the intracellular transmission of the IL-2 signal is dependent on the cytoplasmic tails of CD122 and CD132. In contrast, the intermediate-affinity IL-2R, composed only of CD122 and CD132, is found on resting T and B lymphocytes and cytotoxic immunoregulatory CD56bright NK cells, and binds IL-2 with an affinity significantly lower than the high-affinity CD25-containing IL-2R (Figure 2).

Daclizumab binds selectively and with greater affinity than IL-2 to CD25 expressed on effector T lymphocytes (dissociation constants, 0.27 and 10 nM, respectively), thus blocking the assembly of the high-affinity IL-2R and preventing IL-2 signal transmission via this route (Figure 2). Daclizumab does not block IL-2 signaling via the intermediate-affinity IL-2R on resting T lymphocytes and other immune cells. The primary overall effects of CD25 blockade by daclizumab in patients with RMS are antagonism of proinflammatory, activated T lymphocytes, expansion of CD56bright NK cells, and a reversible reduction in TREG cell numbers (Figure 2).

Daclizumab, by inhibiting the formation of the high-affinity IL-2R, results in an increase in the amount of IL-2 available for interaction with the intermediate-affinity IL-2R expressed on CD56bright NK cells, to which daclizumab cannot bind due to the absence of CD25. Unimpeded activation of the intermediate-affinity IL-2R activates and induces the expansion of CD56bright NK cells, which can penetrate the blood–brain barrier where they recognize, establish direct contact with, and cause lysis of proinflammatory, activated T lymphocytes, while leaving resting T lymphocytes intact. CD25 blockade also may have indirect effects on proinflammatory T lymphocyte responses by inhibiting trans-presentation of CD25 by dendritic cells to the IL-2R on resting T lymphocytes, further preventing the formation of the high-affinity IL-2R. The effects of daclizumab on activated T lymphocytes and CD56bright NK cells are fully reversible after treatment is stopped.

### Figure 2 Proposed mechanism of action of daclizumab and effects on key immune cell populations.

**Notes:** (A) IL-2 binds with higher affinity to the heterotrimeric IL-2R complex composed of CD25, CD122, and CD132 than to the heterodimeric intermediate-affinity IL-2R composed of the CD122 and CD132 subunits. (B) Daclizumab binds to CD25 and prevents formation of the high-affinity receptor complex, which increases the availability of IL-2 to bind and signal through the intermediate-affinity receptor complex. (C) Blockade of CD25 has effects on several different immune cell populations in patients with MS, most notably proinflammatory, activated T lymphocytes, CD56bright NK cells, and TREG cells.

**Abbreviations:** IL-2, interleukin 2 receptor; IL-2, interleukin 2; MS, multiple sclerosis; Tact, activated T cell; NK, natural killer; TREG, regulatory T cell.
As noted earlier, T<sub>REG</sub> cells express the high-affinity CD25-containing IL-2R, and the function of T<sub>REG</sub> cells is believed to be dependent upon IL-2/IL-2R interaction. If this is the case, one might anticipate potential worsening of autoimmunity upon CD25 blockade, but just the opposite is observed. Daclizumab has demonstrated efficacy in reducing MS disease activity, even though treatment with daclizumab results in a reversible reduction in T<sub>REG</sub> cell numbers of ~50%. Several lines of evidence may provide at least partial answers to this seeming paradox. Expression of the T<sub>REG</sub> cell phenotype is largely defined by the presence of FOXP3<sup>+</sup> expression in CD4<sup>+</sup> T lymphocytes. The signal that activates the FOXP3 gene is transmitted via the γ (CD132) chain of IL-2R. Thus, FOXP3 gene activation by IL-2 via the intermediate-affinity receptor may serve to maintain and support the T<sub>REG</sub> population. In addition, the CD132 γ chain, which is found in multiple cytokine receptors, may also be stimulated by other cytokines, such as IL-4, IL-7, IL-9, and IL-21. Daclizumab does not result in T<sub>REG</sub> cell depletion, and evidence suggests that the T<sub>REG</sub> cells that remain preserve the normal T<sub>REG</sub> lineage and phenotype. In this scenario, daclizumab reduces activated T lymphocyte support by IL-2 by blocking CD25 bioavailability, while increasing NK cell activation and maintaining T<sub>REG</sub> cell function and phenotype via the still-available intermediate- and low-affinity receptor subunits of IL-2R and other cytokine receptors.

Lymphoid tissue inducer (LTi) cells are a proinflammatory subset of lymphocytes that appear to originate from hematopoetic CD34<sup>+</sup> precursor cells. Among the proposed actions of LTi cells is the promotion of ectopic lymphoid follicles, as are found in the meninges of patients with MS. The findings of two studies suggest that daclizumab therapy in patients with RMS was associated with a decrease in circulating LTi cells and a decrease in the cerebrospinal fluid content of CXCL13, a chemokine produced by CNS lymphoid aggregates. The reported decrease in LTi cells was hypothesized to be a consequence of increased stimulation of the intermediate-affinity IL-2R due to CD25 blockade by daclizumab, driving its progenitor cells toward the formation of CD56<sup>high</sup> NK cells at the expense of the LTi lineage. In the past few years, studies have shown that innate lymphoid cells are more diverse than previously appreciated. More recently published data do not confirm the previously reported reduction in LTi cells by daclizumab, and may be a result of different analytic methods used in these studies to identify innate lymphoid cell subsets. The findings from this recent study confirmed that circulating CD56<sup>bright</sup> NK cells were increased in patients with RMS treated with daclizumab, but there was no apparent effect of daclizumab on circulating innate lymphoid cell subpopulations, including LTi cells.

Pharmacokinetics

Four studies evaluated the pharmacokinetics of IV daclizumab and SC daclizumab in healthy individuals and patients with RMS. In general, there were no clinically meaningful differences between the two populations in the pharmacokinetic profile of daclizumab, which was characterized by slow clearance, linear pharmacokinetics (doses ≥100 mg), high SC bioavailability (>80%), and an elimination half-life suitable for monthly administration (~3 weeks). Daclizumab had a low volume of distribution of 6.4 L in healthy volunteers, which is to be expected for an immunoglobulin G1 monoclonal antibody that is primarily confined to the vascular and interstitial spaces.

Daclizumab best fits a two-compartment pharmacokinetic model with first-order absorption and elimination, and this finding was used to predict its steady-state pharmacokinetic profile in Phase III studies. Steady-state serum concentrations of daclizumab were attained by week 16 in 26 patients with RMS who received daclizumab 150 mg SC every 4 weeks for 20 weeks (total of six doses) in the Phase III OBSERVE study (NCT01462318). Maximum observed concentration (C<sub>max</sub>) was achieved after a median of 7 and 5 days for doses 1 and 6, respectively, with a mean steady-state serum peak-to-trough concentration ratio of ~2 (Table 2).

There are no known adverse drug–drug interactions in patients treated with daclizumab. In a recently reported study of the effects of daclizumab on the pharmacokinetics of drugs metabolized by a range of hepatic cytochrome P450 isoenzymes, no interaction was seen, co-administration neither inhibiting nor inducing enzymatic activities, and the serum kinetics of medications characteristically metabolized by these isoenzymes were not affected.

Pharmacodynamics

Daclizumab has a well-defined pharmacodynamic profile, demonstrating rapid saturation of CD25 on peripheral blood T lymphocytes within a few hours after SC administration that persisted throughout the 4-week dosing interval, and more slowly reversed following treatment discontinuation. Unbound CD25 returned to pretreatment levels within 4–6 months after the last daclizumab dose due to its long half-life of elimination. The longevity of this effect suggests that delayed or isolated missed doses of daclizumab due to patient nonadherence may have minimal to no adverse impact upon clinical efficacy.
Total CD4+ and CD8+ T lymphocyte counts were modestly reduced in daclizumab-treated patients in the SELECT (mean reductions of 7%–10% over 52 weeks) and DECIDE (median reductions of 15%–18% over 96 weeks) studies. Despite reductions in each of these T lymphocyte populations, the ratio of the number of CD4+ T lymphocytes to CD8+ T lymphocytes remained stable during daclizumab treatment in both studies. Furthermore, no association was observed between CD4+ or CD8+ T lymphocyte counts and the occurrence of infections in daclizumab-treated patients in DECIDE. In contrast, activated effector CD4+ T lymphocytes that express HLA-DR2, a haplotype associated with susceptibility to MS, were reduced by ~25% during the treatment period in daclizumab-treated patients with active RMS in CHOICE, suggesting a selective reduction in activated CD4+ T lymphocytes.

Serum IL-2 levels increased approximately twofold within 4 weeks of daclizumab administration and stabilized thereafter with continued treatment. Accompanying the increased IL-2 levels was a rapid, up to fivofold, increase in the number of CD56bright NK cells, reaching a plateau within 52 weeks that was sustained with continued treatment and subsequently decreased during a placebo washout period. A significant increase in the number of CD56bright NK cells also was observed in cerebrospinal fluid after IV daclizumab administration. Notably, higher CD56bright NK cell counts at week 4 were associated with lower numbers of new or newly enlarging T2 hyperintense lesions over 52 weeks (P<0.001). During the first year of treatment, both the lowest and highest quartiles of peripheral blood CD56bright NK counts at week 8 were associated with fewer new or newly enlarging T2 hyperintense lesions between weeks 24 and 52 (63% and 86%, respectively) compared with placebo (P<0.0001 for each quartile comparison). The observed reduction in MRI measures of disease activity may be the direct result of the cytotoxic effects of CD56bright NK cells upon activated T lymphocytes. However, even in daclizumab-treated patients who experienced no expansion of CD56bright NK cell numbers, there was a 54% reduction in new or newly enlarging T2 hyperintense lesions over 52 weeks versus the placebo group, emphasizing that mechanisms other than the expansion of CD56bright NK cells also contribute to the reduction in MS disease activity. The predictive value of CD56bright NK cell counts measured during the first 4 or 8 weeks after daclizumab initiation upon disease activity during the first 52 weeks of observation was not seen in the second year of daclizumab therapy.

In addition, TREG cells express CD25, and reductions in TREG cell counts of ~50% that persisted throughout the duration of treatment have been observed in daclizumab-treated patients. The effect of daclizumab on TREG cell counts is reversible on treatment discontinuation and nondepleting because remaining TREG cells maintain the TREG function and phenotype (ie, do not acquire effector CD4+ T lymphocyte characteristics). No association has been found to date between daclizumab-mediated declines in TREG cell numbers and clinical efficacy during treatment. Daclizumab shows continued efficacy in RMS despite reducing the number of TREG cells. This reduction in TREG cell numbers may in part be compensated for by daclizumab-induced expansion of CD56bright NK cells, the latter playing a significant role in restoring immune tolerance through their destruction of pro-inflammatory T cells, and thus may be a major mediator of the effects of daclizumab on RMS disease activity.

### Efficacy

#### Pivotal studies

Two large double-blind controlled studies compared daclizumab 150 mg SC every 4 weeks with placebo over 52 weeks (SELECT) and with intramuscular (IM) interferon beta-1a 30 mcg once weekly for a minimum of 96 weeks and up to a
maximum of 144 weeks (DECIDE; Table 1 and Figure 1).42 Eligible patients were adults (18–55 years of age) with documented relapsing–remitting MS according to the 2005 McDonald criteria.109 The primary endpoint in both SELECT and DECIDE was the annualized relapse rate (ARR), where relapse was defined as new or recurrent neurological symptoms not associated with fever or infection, lasting 24 hours or more, and accompanied by new or worsened objective neurological findings at assessment.110 Secondary and tertiary outcomes included the impact of daclizumab on confirmed disability worsening, MRI lesion burden and activity, patient-reported outcomes, safety, and immune system activity markers. SELECT (and its extension study, SELECTION; Figure 1) also included a daclizumab 300 mg treatment group, but because efficacy outcomes were similar between the 150 and 300 mg dose groups, only the 150 mg dose was evaluated in subsequent pivotal studies in MS.110 Thus, this review focuses on results from treatment with daclizumab 150 mg.

The primary endpoint was met in both SELECT and DECIDE; ARR was reduced significantly by daclizumab 150 mg compared with placebo over 52 weeks in SELECT (54% reduction; P<0.0001) and compared with IM interferon beta-1a over 144 weeks in DECIDE (45% reduction; P<0.001; Table 3).41,42 In DECIDE, daclizumab also significantly reduced the annualized rate of severe/serious relapses (38% reduction; P=0.002).42 In SELECT, there was a 57% reduction in 12-week confirmed disability worsening with daclizumab (P=0.021).41 In DECIDE, there was a 16% difference in the percentage of patients with 12-week confirmed disability worsening that favored daclizumab, but the effect was not statistically significant (P=0.16).42 However, there was an imbalance between treatment arms in the number of patients censored who experienced disability worsening, but left the study before disability worsening could be confirmed 12 weeks later, which was considered to have impacted the test for statistical significance. Specifically, the primary analysis assumed that none of the censored patients had 12-week confirmed disability worsening. However, when all censored patients were instead assumed to have 12-week confirmed disability worsening, a 24% reduction in 12-week confirmed disability worsening was observed for daclizumab versus IM interferon beta-1a (P=0.016).42 When censored patients were assumed as either confirmed or not confirmed based on an imputation of the observed rate, a 21% reduction in 12-week confirmed disability worsening was observed that favored daclizumab (P=0.047).42 DECIDE also included assessment of 24-week confirmed disability worsening – considered by the EMA to be a more robust measure than 12-week confirmed disability worsening411 – as a preplanned tertiary endpoint using the imputed methodological approach.42 Daclizumab significantly reduced 24-week confirmed disability worsening by 27% compared with IM interferon beta-1a (P=0.03).42

Consistent with the effects of daclizumab on clinical endpoints, statistically significant effects were observed on MRI measures of disease activity in both SELECT and DECIDE (Table 4).41,42 At week 52 in SELECT and week 96 in DECIDE, daclizumab 150 mg significantly reduced the number of gadolinium-enhancing (Gd⁺) lesions (new Gd⁺

---

Table 3 Clinical efficacy of daclizumab 150 mg given subcutaneously every 4 weeks in multicenter, randomized, double-blind, comparative studies of patients with RMS41,42

<table>
<thead>
<tr>
<th>Study treatment group</th>
<th>Patients, n°</th>
<th>ARR (95% CI) Relapse free, %</th>
<th>12-week confirmed disability worsening, %</th>
<th>24-week confirmed disability worsening, %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SELECT data at week 52</strong>41</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>196</td>
<td>0.46 (0.37–0.57) 64</td>
<td>13</td>
<td>NE</td>
</tr>
<tr>
<td>Daclizumab 150 mg</td>
<td>201</td>
<td>0.21 (0.16–0.29) 81</td>
<td>6</td>
<td>NE</td>
</tr>
<tr>
<td>Daclizumab 150 mg versus placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54 (33–68);</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DECIDE data at week 144</strong>42</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM interferon beta-1a</td>
<td>922</td>
<td>0.39 (0.35–0.44) 51</td>
<td>20</td>
<td>18</td>
</tr>
<tr>
<td>Daclizumab 150 mg</td>
<td>919</td>
<td>0.22 (0.19–0.24) 67</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td>Daclizumab 150 mg versus IM interferon beta-1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45 (36–53);</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P&lt;0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM interferon beta-1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.39 (0.35–0.44) 51</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Notes:</strong> Results are presented for efficacy analysis populations. Results from the daclizumab 300 mg treatment arm have been reported,41 but are not included in this table comparing efficacy outcomes of the 150 mg dose. In both the DECIDE and SELECT studies, between treatment group differences in ARR were evaluated using negative binomial regression models. Times to first relapse or to confirmed disability worsening and proportion of patients with relapse or confirmed disability worsening were estimated based on Kaplan–Meier survival distribution and between-treatment-group differences were evaluated using Cox proportional-hazards models. Each of the models included adjustments for baseline factors. In the analysis of 24-week confirmed disability worsening in DECIDE, patients with a missing confirmatory assessment after a tentative progression were imputed using multiple imputation based on risk factors at time of tentative progression. The statistical models are detailed in the original articles.41–42 SELECT data adapted with permission from Elsevier (The Lancet, 2013, 381, 2167–75). Abbreviations: RMS, relapsing multiple sclerosis; ARR, annualized relapse rate; CI, confidence interval; NE, not evaluated; HR, hazard ratio; IM, intramuscular.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
lesions in SELECT, $P<0.0001$, and all Gd$^+$ lesions in DECIDE, $P<0.001$, respectively) and new or newly enlarging T2 hyperintense lesions ($P<0.0001$ and $P<0.001$, respectively).$^{41,42}$ In DECIDE, the effects on both of these MRI lesion parameters were observed as early as the first MRI assessment at week 24 ($P<0.001$ for both measures),$^{42}$ while in SELECT, the effect on new Gd$^+$ lesions was seen as early as 4 weeks after initiating treatment, which was the time of the first post-baseline MRI.$^{41}$ The mean percentage of brain volume loss, which may be indicative of neurodegeneration and tissue damage,$^{112}$ was not significantly different between treatment groups after 2 years of treatment in DECIDE ($P>0.001$; Table 4).$^{41,42}$ A benefit for daclizumab over IM interferon beta-1a on brain volume loss also was observed during the intervals of baseline to week 24 ($P=0.03$) and weeks 24–96 ($P<0.001$).$^{42}$ The effects of daclizumab across all MRI lesion outcomes were maintained in the subgroup of patients treated for 144 weeks.$^{113,114}$

A post hoc subgroup analysis of SELECT revealed statistically significant reductions in ARR, new or newly enlarging T2 hyperintense lesions, and new Gd$^+$ lesions with daclizumab compared with placebo in patients with highly active RMS, defined as at least two relapses in the year before randomization and at least one Gd$^+$ lesion at baseline.$^{115}$ A benefit for daclizumab versus IM interferon beta-1a on relapse and MRI lesion activity in patients with highly active RMS also has been reported in DECIDE.$^{116}$ In DECIDE, the clinical and MRI benefits of daclizumab were consistent across a number of predefined patient subgroups stratified by

### Table 4 Neuroradiological efficacy of daclizumab 150 mg given subcutaneously every 4 weeks in multicenter, randomized, double-blind, comparative studies of patients with RMS$^{41,42}$

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SELECT (week 52 data)</th>
<th>DECIDE (week 96 data)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo n=196</td>
<td>Daclizumab 150 mg n=201</td>
</tr>
<tr>
<td>New Gd$^+$ lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>195</td>
<td>199</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.4 (2.3)</td>
<td>0.3 (0.9)</td>
</tr>
<tr>
<td>Odds ratio (95% CI); P-value</td>
<td>—</td>
<td>0.15 (0.09–0.25); $P&lt;0.0001$</td>
</tr>
<tr>
<td>Gd$^+$ lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Odds ratio (95% CI); P-value</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>New or newly enlarging T2 hyperintense lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>195</td>
<td>199</td>
</tr>
<tr>
<td>Mean (95% CI)</td>
<td>8.1 (6.7–9.9)</td>
<td>2.4 (2.0–3.0)</td>
</tr>
<tr>
<td>Reduction, %; P-value</td>
<td>—</td>
<td>70 (59.4–77.9); $P&lt;0.0001$</td>
</tr>
<tr>
<td>New T1 hypointense lesions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mean (95% CI)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Reduction, %; P-value</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>% change from baseline in T2 hyperintense lesion volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>193</td>
<td>198</td>
</tr>
<tr>
<td>Mean (SD); P-value</td>
<td>27.3 (107.8)</td>
<td>$–11.1$ (12.1); $P&lt;0.0001$</td>
</tr>
<tr>
<td>% change from baseline in T1 hypointense lesion volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>180</td>
<td>187</td>
</tr>
<tr>
<td>Mean (SD); P-value</td>
<td>18.0 (110.4)</td>
<td>$–10.5$ (25.7); $P&lt;0.0001$</td>
</tr>
<tr>
<td>% mean change from baseline in whole brain volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>194</td>
<td>198</td>
</tr>
<tr>
<td>Mean (SD); P-value</td>
<td>$–0.74$ (0.90)</td>
<td>$–0.79$ (0.83); $P&lt;0.03$</td>
</tr>
</tbody>
</table>

**Notes:** Results are presented for patients in the efficacy analysis population who had a post-baseline scan.$^{41,42}$ Results from the daclizumab 300 mg treatment arm have been reported,$^{41}$ but are not included in this table comparing efficacy outcomes of the 150 mg dose. SD not reported. In both the DECIDE and SELECT studies, between treatment group differences were evaluated using ordinal logistic regression models (new Gd$^+$/Gd$^+$ lesions), negative binomial regression models (new or newly enlarging T2 lesions, new T1 hypointense lesions), or analysis of covariance model based on ranks (T2 hyperintense and T1 hypointense lesion volume, whole brain volume). Each of the models included adjustments for baseline factors. The statistical models are detailed in the original articles.$^{41,42}$ SELECT data adapted with permission from Elsevier (The Lancet, 2013, 381, 2167–75).

**Abbreviations:** RMS, relapsing multiple sclerosis; IM, intramuscular; IFN, interferon; Gd$^+$, gadolinium-enhancing; SD, standard deviation; CI, confidence interval.
Additional post hoc analyses examined the proportion of patients with NEDA, defined as no relapses, no confirmed disability worsening, no new Gd+ lesions (SELECT) or no Gd+ lesions (DECIDE), and no new or newly enlarging T2 hyperintense lesions on brain MRI.18,118 In SELECT, a significantly higher percentage of patients receiving daclizumab 150 mg compared with placebo exhibited NEDA at week 52 (36% versus 11%; adjusted odds ratio 6.31; 95% confidence interval [CI] 3.59–11.11; \( P<0.0001 \)). Similarly, in DECIDE, a significantly higher percentage of patients receiving daclizumab 150 mg compared with IM interferon beta-1a exhibited NEDA at week 96 (25% versus 14%; odds ratio 2.06; 95% CI 1.59–2.66; \( P<0.0001 \)).118

**Extension studies**

Both SELECT and DECIDE are being followed up with extension phases, enabling evaluation of the long-term safety profile and persistence of daclizumab efficacy (Figure 1).51–53,120 Final results are available for SELECTION, a 1-year extension of SELECT,52 and interim 3-year results for SELECTED, an ongoing, long-term, open-label extension of SELECTION.53 In SELECT, half of the patients who received daclizumab 150 mg SC in SELECT were randomized to continue daclizumab 150 mg SC for an additional year (Table 1 and Figure 1). Patients who completed SELECTION were then eligible to enroll in the SELECTED long-term extension study (Figure 1).53 For patients who received daclizumab 150 mg for 1 year in SELECT and continued to receive daclizumab 150 mg for an additional year in SELECTED, the ARR (0.148 and 0.165), the proportion of patients with relapse (14.7% and 13.6%), and the proportion of patients with 12-week confirmed disability worsening (6% and 5%) were similar in years 1 and 2 of treatment, respectively.52 In the subset of patients (n=94) in SELECTED who had received continuous daclizumab 150 mg since their initial enrollment in SELECT, efficacy outcomes were sustained in the third year of treatment.53 EXTEND is an ongoing open-label extension study of DECIDE, from which no interim data have yet been reported, that will provide additional information on the long-term safety and efficacy of daclizumab for up to 6 years of treatment.51

**Patient-centered outcomes**

Consistent with the effects of daclizumab on primary and secondary clinical and MRI endpoints in SELECT and DECIDE, significant benefits of daclizumab were observed on health-related quality-of-life measures.41,42 Patient-reported outcomes in both studies included the 29-item Multiple Sclerosis Impact Scale (MSIS-29), which is used to assess the impact of MS on physical (physical impact subscale [PHYS]) and psychological (psychological impact subscale) functioning,121 as well as the EuroQol 5-Dimensions (EQ-5D), which is used to assess general health status.122 The EQ-5D includes a descriptive component in which patients self-report their current level of difficulty on five dimensions of health (index score) and a valuation component in which patients self-rate their general health status on a visual analog scale (VAS).122

In SELECT, a statistically significant benefit for daclizumab 150 mg compared with placebo was observed on MSIS-29 PHYS subscale (\( P=0.00082 \)), ED-5D index (\( P=0.0091 \)), and EQ-5D VAS (\( P<0.0001 \)) scores (Figure 3).41 In DECIDE, significantly greater mean improvements from baseline were observed at week 96 with daclizumab 150 mg compared with IM interferon beta-1a on MSIS-29 PHYS subscale (\( P<0.001 \)), MSIS-29 psychological impact subscale (\( P=0.04 \)), EQ-5D index (\( P=0.005 \)), and EQ-5D VAS (\( P<0.001 \)) scores (Figure 3).42 Clinically meaningful worsening on the MSIS PHYS subscale has been defined as a \( \geq 7.5 \)-point change from baseline,110 and this was evaluated post hoc in SELECT and as a secondary outcome in DECIDE.42,110 In SELECT, significantly fewer patients treated with daclizumab 150 mg compared with placebo exhibited clinically meaningful worsening on the MSIS-29 PHYS subscale at week 52 (20% versus 28%, respectively; \( P<0.01 \)).119 In DECIDE, significantly fewer patients treated with daclizumab 150 mg compared with IM interferon beta-1a exhibited clinically meaningful worsening on the MSIS-29 PHYS subscale at week 96 (19% versus 23%, respectively), representing a 24% relative reduction in the odds for worsening between treatment groups (95% CI 5–40; \( P=0.0176 \)).122

The Multiple Sclerosis Functional Composite (MSFC) was administered in DECIDE. The MSFC is a quantitative measure with three components assessing lower limb function/walking ability (Timed 25-Foot Walk [T25FW]), upper limb function (9-Hole Peg Test [9HPT]), and cognitive function (3-second Paced Auditory Serial Addition Test [PASAT-3]).124 At week 96 of DECIDE, daclizumab 150 mg was associated with a greater improvement baseline in MSFC composite score compared with IM interferon beta-1a (0.091 versus 0.055, respectively; \( P<0.001 \)).122 Significant benefits of daclizumab treatment versus IM interferon beta-1a also were seen on all three separate components that comprise the MSFC at week 96 (T25FW [\( P=0.006 \)], 9HPT [\( P=0.002 \)], and PASAT-3 [\( P=0.04 \)]). A2 Benefit for daclizumab on cognitive outcomes also was observed
on the Symbol Digit Modalities Test at week 96 with greater mean improvements from baseline observed for daclizumab (4.1±12.4) versus IM interferon beta-1a (2.9±12.7; P=0.03).42

**Safety and tolerability**

Two decades of clinical experience with interferon beta and glatiramer acetate have shown that these DMTs are relatively safe, although serious adverse events (AEs) do infrequently occur.125,126 Newer DMTs, including natalizumab, fingolimod, delayed-release dimethyl fumarate, teriflunomide, and alemtuzumab, have improved on the modest efficacy outcomes achieved with interferon beta and glatiramer acetate; however, each is associated with a greater degree of concern regarding safety or tolerability.17,125,127,128 It is important to have a clear understanding of the safety profile of each DMT in order to weigh potential risks against potential benefits.
Safety data have been reported for SELECT, SELECTION, and DECIDE (Table 5). The overall incidence of AEs was similar between daclizumab and placebo in SELECT and between daclizumab and IM interferon beta-1a in DECIDE (Table 5). The incidence of serious AEs, excluding MS relapse, was similar in the daclizumab and placebo groups after 1 year of treatment in SELECT, but was higher in daclizumab-treated patients than in IM interferon beta-1a-treated patients after 2–3 years of treatment in DECIDE (Table 5). Most treatment-emergent AEs in patients receiving daclizumab were mild or moderate in severity, and the incidence of these AEs did not increase with increasing duration of treatment.

Daclizumab treatment was associated with a higher incidence of AEs leading to treatment discontinuation compared with both placebo (3% versus <1%) and IM interferon beta-1a (15% versus 12%), respectively. There was no evidence of an increased risk of malignancies in either SELECT or DECIDE, and rates were similar between comparator arms (Table 5). Five deaths were reported in patients treated with daclizumab during the clinical studies; in two of them (ischemic colitis as a complication of psoas abscess and autoimmune hepatitis in a patient treated with daclizumab 300 mg), a contributory role for daclizumab could not be ruled out, while the other three

### Table 5 Incidence of AEs in daclizumab 150 mg-treated patients in SELECT, SELECTION, and DECIDE

<table>
<thead>
<tr>
<th>Safety parameter, n (%)</th>
<th>SELECT (52 weeks)</th>
<th>SELECTION (year 1)</th>
<th>SELECTION (year 2)</th>
<th>DECIDE (144 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo n=204</td>
<td>Daclizumab 150 mg n=208</td>
<td>Daclizumab 150 mg n=86</td>
<td>Daclizumab 150 mg n=86</td>
</tr>
<tr>
<td>Any AE</td>
<td>161 (79)</td>
<td>151 (73)</td>
<td>61 (71)</td>
<td>57 (66)</td>
</tr>
<tr>
<td>Any serious AE</td>
<td>53 (26)</td>
<td>32 (15)</td>
<td>15 (17)</td>
<td>15 (17)</td>
</tr>
<tr>
<td>Any serious AE, excluding MS relapse</td>
<td>12 (6)</td>
<td>15 (7)</td>
<td>7 (8)</td>
<td>6 (7)</td>
</tr>
<tr>
<td>Treatment discontinuation due to AE</td>
<td>2 (&lt;1)</td>
<td>6 (3)</td>
<td>3 (3)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1 (&lt;1)</td>
<td>0 (&lt;1)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Death</td>
<td>0 (&lt;1)</td>
<td>0 (&lt;1)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs of special interest</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td>89 (44)</td>
<td>104 (50)</td>
<td>34 (40)</td>
<td>36 (42)</td>
</tr>
<tr>
<td>Serious infections</td>
<td>0 (&lt;1)</td>
<td>6 (3)</td>
<td>3 (3)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Cutaneous events</td>
<td>27 (13)</td>
<td>38 (18)</td>
<td>17 (20)</td>
<td>15 (17)</td>
</tr>
<tr>
<td>Serious cutaneous events</td>
<td>0 (&lt;1)</td>
<td>2 (&lt;1)</td>
<td>2 (2)</td>
<td>0</td>
</tr>
<tr>
<td>Hepatic event&lt;sup&gt;c&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Serious hepatic event&lt;sup&gt;c&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hepatic laboratory abnormalities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT or AST 1–3× ULN</td>
<td>64 (31)</td>
<td>54 (26)</td>
<td>23 (27)</td>
<td>30 (35)</td>
</tr>
<tr>
<td>ALT or AST 3–5× ULN</td>
<td>6 (3)</td>
<td>7 (3)</td>
<td>0</td>
<td>1 (1)</td>
</tr>
<tr>
<td>ALT or AST ≥2× ULN</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>80 (9)</td>
</tr>
<tr>
<td>ALT or AST &gt;5× ULN</td>
<td>1 (&lt;1)</td>
<td>9 (4)</td>
<td>1 (1)</td>
<td>0</td>
</tr>
<tr>
<td>ALT or AST ≥3× ULN</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>and total bilirubin &gt;2× ULN</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hy’s law cases&lt;sup&gt;d&lt;/sup&gt;</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>AEs by severity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Moderate</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Severe</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Injection site reactions</td>
<td>3 (1)</td>
<td>4 (2)</td>
<td>2 (2)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Influenza-like symptoms</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

**Notes:** Results from the daclizumab 300 mg treatment arms in SELECT and SELECTION and the daclizumab 150 mg washout and reinitiation arm in SELECTION have been reported, but are not included in this table showing the safety profile of continuous treatment with the 150-mg dose. Dashes are used where data were not reported for the parameter. Year 1 represents patients in the placebo group in SELECT who were randomized to initiate treatment with daclizumab 150 mg in SELECTION, and year 2 represents patients in the daclizumab 150 mg group in SELECT who were randomized to continue daclizumab 150 mg treatment in SELECTION. One death (autoimmune hepatitis) was reported in SELECTION in a patient randomized to washout for 24 weeks followed by reinitiation of daclizumab 300 mg. Defined using the standardized Medical Dictionary for Regulatory Activities query for drug-related hepatic disorders. The patient in each treatment group was assessed by an independent panel to meet the criteria of Hy’s law based on a causality score of probable or higher. There were no cases assessed as having a causality score of definitive. SELECT and SELECTION data adapted with permission from Elsevier (The Lancet, 2013, 381, 2167–75) and (Lancet Neurology, 2014, 13, 472–81), respectively.

**Abbreviations:** AE, adverse event; IM, intramuscular; IFN, interferon; MS, multiple sclerosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.
for patients in SELECT and SELECTION after 1 year of treatment (Table 5). The safety profile of daclizumab after extended treatment was similar to that observed in SELECT and SELECTION.

Hepatic AEs, including liver enzyme elevations, have been observed in daclizumab treatment groups, but the incidence of treatment-limiting events is low (Table 5). Similar percentages of patients had elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 1–3× the upper limit of normal (ULN) in the daclizumab and placebo groups after 1 year of treatment in SELECT (Table 5). The incidence of elevations of ALT or AST 1–3× ULN was slightly higher in patients in year 2 of treatment than in year 1 of treatment in SELECT; however, the incidence of ALT or AST elevations >5× ULN was similar in years 1 and 2 of treatment (Table 5). Elevations of ALT or AST >5× ULN were more common with daclizumab 150 mg than with placebo (4% versus <1%) or IM interferon beta-1a (6% versus 3%), respectively (Table 5). Elevated serum transaminases were observed throughout the treatment period in the daclizumab group, but occurred predominantly in the early phases of treatment in the IM interferon beta-1a group. In DECIDE, drug-related hepatic events, as defined by a Medical Dictionary of Regulatory Activities query, were observed in 16% of daclizumab-treated patients and 14% of IM interferon beta-1a-treated patients, with serious hepatic events occurring in 1% and <1% of patients, respectively. Seven patients receiving daclizumab and one patient receiving IM interferon beta-1a experienced ALT or AST >3× ULN concurrent with total bilirubin >2× ULN. However, the independent hepatic safety assessment concluded that only one patient in each treatment group that met the criteria for Hy’s law had a causality score of probable or higher (Table 5).

Daclizumab has been associated with an increased risk of cutaneous AEs when compared with placebo or IM interferon beta-1a (Table 5). In DECIDE, cutaneous AEs occurred in 37% of daclizumab-treated patients and 19% of IM interferon beta-1a-treated patients over 2–3 years of treatment and resulted in treatment discontinuation in 5% and 1% of patients, respectively. The most common cutaneous events were rash (7% versus 3% of patients) and eczema (4% versus 1%) in the daclizumab and IM interferon beta-1a groups, respectively. Most patients with cutaneous AEs had mild (55%) or moderate (38%) events, and these events were predominantly treated with topical corticosteroids or did not require any topical or systemic corticosteroid treatment (ie, 81% of mild and 73% of moderate events). Severe or serious cutaneous AEs were each reported in 2% of daclizumab-treated patients and most commonly were treated with systemic corticosteroids. Among patients with serious cutaneous events in the daclizumab group, dermatitis was reported in three patients and angioedema in two patients; all other serious cutaneous events were reported in one patient each. There were no cases of Stevens–Johnson syndrome or toxic epidermal necrolysis reported in DECIDE.

In SELECTED, one case was reported by the investigator as Stevens–Johnson syndrome, but the diagnosis was not supported by the study’s central independent dermatologist or by the local site dermatologist upon their review of the case. Both infections and serious infections have been observed at a higher incidence in daclizumab-treated patients compared with those treated with placebo or IM interferon beta-1a (Table 5). Most patients with infections remained on daclizumab treatment. The most common (incidence ≥10%) infections in DECIDE were nasopharyngitis (25% versus 21%), upper respiratory tract infection (16% versus 13%), and urinary tract infection (10% versus 11%) in the daclizumab and IM interferon beta-1a groups, respectively. In SELECT and SELECTION, most patients stayed on daclizumab treatment or restarted daclizumab treatment after resolution of their serious infection. No cases of progressive multifocal leukoencephalopathy have been reported to date in the daclizumab clinical study program. Interim analyses of safety extension studies showed that the risk of infections did not increase with longer duration of treatment with daclizumab (up to 6 years).

Antidrug antibodies (ADAs) and neutralizing antibodies (NABs) have been detected in relatively low proportions of daclizumab-treated patients. In patients who initiated daclizumab treatment in SELECT, 4% of patients were ADA positive and 2% of patients were NAB positive during the 52-week treatment period. In these patients, NABs were not persistent, because patients who tested positive at week 72 were negative for NABs at week 104. In patients continuing daclizumab treatment in SELECT, one patient was ADA positive, and there were no new cases of NAB positivity in the second year of treatment. In DECIDE, ADAs were observed in 19% of evaluable patients treated with daclizumab; in 7% of patients, ADAs were persistent (defined as more than one consecutive positive evaluation ≥74 days apart or a positive evaluation at the final assessment with no further samples detected).
NAbs were observed in 8% of evaluable patients treated with daclizumab; in 2% of patients, NAbs were persistent. The majority of ADA reactivity to daclizumab occurred early during treatment (during the first year), and this reactivity was transient. ADA titers were generally low in DECIDE, and ADAs and NAbs had no discernible impact on efficacy or safety outcomes associated with daclizumab.

There was no evidence of increased risk of adverse pregnancy outcomes or fetal abnormalities following gestational exposure to daclizumab during the first trimester. Because the number of pregnancies occurring during the daclizumab clinical studies was small (45 pregnancies in 40 patients), no definitive conclusions can be drawn regarding safety during pregnancy. There is no information available on the safety of daclizumab in breastfeeding women.

A substudy of daclizumab-treated patients enrolled in SELECTED who received seasonal influenza vaccination achieved acceptable levels of serologic protection against the seasonal influenza and experienced no unique or worsened safety issues associated with vaccination.

**Administration/acceptability**

Poor adherence to self-injectable DMT regimens may lead to suboptimal treatment outcomes for patients with MS. Furthermore, higher frequency of injection has been associated with reduced adherence. Daclizumab has several properties that may improve use on a long-term basis. First, self-administration of daclizumab on a once-monthly schedule is likely to be better adhered to by more patients than the daily to twice-monthly administration schedules of other DMTs, because reduced patient adherence to MS medications is clearly related to the frequency of administration. Furthermore, reducing the dosing frequency of drugs in indications other than MS has been shown to be associated with better treatment adherence, health-related quality of life, patient satisfaction, and reduced costs. The relatively simple and infrequent procedure of SC administration is unlikely to be a barrier to routine use, and the favorable pharmacokinetic and pharmacodynamic profile of daclizumab should minimize the risk of breakthrough disease activity resulting from delayed dosing. Second, the superior therapeutic profile of daclizumab compared with platform MS medications such as interferon beta-1a, a standard of care in MS, has been demonstrated. The risks associated with daclizumab, including hepatic disorders, cutaneous events, and infections, were typically mild or moderate in severity, manageable with routine medical care, and did not appear to increase with extended treatment. Daclizumab has been approved by the US FDA and EMA for relapsing MS.

**Conclusion**

Management of RMS can be challenging for clinicians because of highly variable intra- and inter-individual therapeutic responses regarding efficacy and safety. Only a minority of patients attain the goal of NEDA with current DMTs, while the majority of patients achieve a partial reduction in the frequency of relapses and inflammatory brain lesion activity on MRI, and delayed accumulation of disability. It is important to note that although patients with residual clinical or radiologic disease activity despite treatment with a first-line DMT may be experiencing some therapeutic benefit, they are commonly at increased risk of disability worsening in the short term and a lower health-related quality of life. Apart from a high incidence of breakthrough disease activity associated with first-line DMTs, many patients experience treatment-related AEs as well as reduced quality of therapeutic response to the extent that clinical and pharmacoeconomic outcomes are compromised because of patient nonadherence to therapy. Hence, new therapies are required that have a favorable benefit–risk profile, few tolerability issues, and different attributes to encourage improved levels of adherence. In this regard, the superior efficacy of daclizumab over IM interferon beta-1a, a standard of care in MS, has been demonstrated. The daclizumab clinical development program was funded by Biogen and AbbVie Biotherapeutics Inc. Biogen and AbbVie Biotherapeutics Inc. provided funding for medical writing support in the development of this paper; Malcolm Darkes from Excel Scientific Solutions wrote the first draft of the manuscript based on input from Dr Cohan, and Kristen DeYoung from Excel Scientific Solutions copyedited and
styled the manuscript per journal requirements. Biogen and AbbVie Biotherapeutics Inc. reviewed and provided feedback on the paper to Dr Cohan. Dr Cohan had full editorial control of the paper and provided his final approval of all content.

Disclosure
Stanley Cohan serves on advisory boards for Biogen, Mallinckrodt, Novartis, and Sanofi-Genzyme; has received research support from Biogen, Mallinckrodt, Novartis, Opexa, Roche-Genentech, Sanofi-Genzyme, and Teva; has received speaker honoraria from Acorda, Biogen, Novartis, Roche-Genentech and Sanofi-Genzyme; and has received funds for transportation, meals, and lodging from Acorda, Biogen, Mallinckrodt, Novartis, Roche-Genentech, and Sanofi-Genzyme. The author reports no other conflicts of interest in this work.

References


For personal use only.

100. Rogers WO, Weaver CT, Kraus LA, Li J, Li L, Bucy RP. Visualization


